Affinity Asset Advisors’s GreenLight Biosciences Holdings, PBC Common Stock GRNA Stock Holding History

Affinity Asset Advisors’s Portfolio GRNA Stock Details GRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-300,000	Closed	-$2.98M	–	78
2021 Q4	$2.98M	Hold	300,000	–	–	1.08%	35
2021 Q3	$2.97M	Buy	+300,000	New	+$2.94M	0.75%	34

Other funds holding GRNA

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

VK Services Menlo Park, California $543K AUM 174.84% 1-Year Est. Return

CGC

Continental Grain Company New York $366M AUM 0.18% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

TCM

Tao Capital Management San Francisco, California $119M AUM 87.46% 1-Year Est. Return

BOTOTLSJU

Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

OCMH

Oxbow Capital Management (HK) Hong Kong $371M AUM 383.45% 1-Year Est. Return

Affinity Asset Advisors's GRNA Position: Q1 2022 in Review

Affinity Asset Advisors sold out of GreenLight Biosciences Holdings, PBC Common Stock (GRNA) in Q1 2022, closing a stake of 300,000 shares — an estimated $2.98M sold.

Affinity Asset Advisors first reported a position in GRNA in Q3 2021 and held it in 2 quarters. The position peaked at $2.98M in Q4 2021. 39 funds tracked by Wall St. Rank hold GRNA as of Q1 2022.

Affinity Asset Advisors reported no remaining GreenLight Biosciences Holdings, PBC Common Stock position as of Q1 2022 after selling out during the quarter.
Affinity Asset Advisors sold 300,000 GreenLight Biosciences Holdings, PBC Common Stock shares in Q1 2022, an estimated $2.98M.
Affinity Asset Advisors first reported a position in GreenLight Biosciences Holdings, PBC Common Stock in Q3 2021 and held it in 2 quarters.
Affinity Asset Advisors's GreenLight Biosciences Holdings, PBC Common Stock position peaked at $2.98M in Q4 2021.
39 funds tracked by Wall St. Rank held GreenLight Biosciences Holdings, PBC Common Stock as of Q1 2022.

Based on Affinity Asset Advisors's 13F filing for Q1 2022, filed 13 May 2022.